Published in Nat Genet on November 21, 2004
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol (2008) 3.93
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol (2007) 2.70
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell (2012) 2.05
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest (2006) 2.02
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A (2005) 1.96
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol (2009) 1.79
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 1.57
Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice. Hepatology (2015) 1.56
Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations. J Vasc Interv Radiol (2012) 1.54
Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet (2009) 1.52
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab (2011) 1.47
Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures. Nucleic Acids Res (2010) 1.45
Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol (2013) 1.39
Transcript-level annotation of Affymetrix probesets improves the interpretation of gene expression data. BMC Bioinformatics (2007) 1.35
Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol (2008) 1.33
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 1.32
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol (2012) 1.32
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res (2011) 1.32
Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci U S A (2012) 1.31
Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One (2012) 1.28
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair (2013) 1.27
The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res (2012) 1.27
Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol (2008) 1.26
Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet (2008) 1.23
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut (2012) 1.22
mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med (2012) 1.21
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (2008) 1.16
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J (2009) 1.13
A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. Dis Model Mech (2011) 1.13
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int (2010) 1.12
Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol (2006) 1.07
Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05
Alpha-fetoprotein-thymidine kinase-luciferase knockin mice: a novel model for dual modality longitudinal imaging of tumorigenesis in liver. J Hepatol (2010) 1.04
Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. Am J Pathol (2011) 1.04
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis (2010) 1.02
Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology (2013) 1.02
A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors. Dis Model Mech (2012) 1.00
Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer (2008) 0.99
Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res (2014) 0.99
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer (2013) 0.98
Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res (2014) 0.98
Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med (2011) 0.97
Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics (2007) 0.97
Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis (2011) 0.97
The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene (2015) 0.95
Xmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma. PLoS One (2014) 0.93
The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol Cancer (2010) 0.92
Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer (2010) 0.91
Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol Sci (2013) 0.91
Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. J Gastroenterol Hepatol (2012) 0.91
AS30D model of hepatocellular carcinoma: tumorigenicity and preliminary characterization by imaging, histopathology, and immunohistochemistry. Cardiovasc Intervent Radiol (2012) 0.90
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget (2016) 0.90
Defining Mononuclear Phagocyte Subset Homology Across Several Distant Warm-Blooded Vertebrates Through Comparative Transcriptomics. Front Immunol (2015) 0.89
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol (2011) 0.88
Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene (2011) 0.88
Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer (2010) 0.87
Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. J Biol Chem (2012) 0.86
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics (2007) 0.86
MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation. Oncotarget (2015) 0.86
Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis (2011) 0.86
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med (2016) 0.85
Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology (2015) 0.84
A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia (2010) 0.84
Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. Environ Mol Mutagen (2008) 0.84
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients. Sci Rep (2015) 0.83
Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One (2011) 0.83
Next-generation sequencing: application in liver cancer-past, present and future? Biology (Basel) (2012) 0.83
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24
The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A (2010) 3.18
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology (2008) 2.91
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol (2010) 2.37
ADGO: analysis of differentially expressed gene sets using composite GO annotation. Bioinformatics (2006) 2.23
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal (2010) 2.08
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
GAzer: gene set analyzer. Bioinformatics (2007) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology (2005) 1.90
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene (2004) 1.90
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood (2010) 1.77
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene (2004) 1.65
Coactivator MED1 ablation in keratinocytes results in hair-cycling defects and epidermal alterations. J Invest Dermatol (2011) 1.64
Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol (2009) 1.60
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell (2002) 1.57
Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta (2007) 1.56
Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med (2014) 1.53
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene (2003) 1.52
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett (2005) 1.45
Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45
Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance. Cell Metab (2006) 1.44
EDGE: a centralized resource for the comparison, analysis, and distribution of toxicogenomic information. Mol Pharmacol (2005) 1.43
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res (2008) 1.41
Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARalpha-regulated gene expression in liver. J Biol Chem (2004) 1.40
Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene (2005) 1.39
HGF attenuates thrombin-induced endothelial permeability by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. FASEB J (2007) 1.39
RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology (2007) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci U S A (2002) 1.36
Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology (2004) 1.35
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology (2006) 1.34
Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology (2012) 1.33
Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology (2004) 1.33
Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors. J Biol Chem (2001) 1.32
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development (2009) 1.31
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology (2008) 1.29
Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One (2012) 1.28
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. Hepatology (2006) 1.27
Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-mediated adipogenesis. J Biol Chem (2003) 1.27
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology (2010) 1.26
Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer. J Hepatol (2005) 1.25
Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol (2005) 1.25
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis (2005) 1.24
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med (2010) 1.23
Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma. J Biol Chem (2007) 1.23
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (2011) 1.22
mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med (2012) 1.21
Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am J Pathol (2005) 1.18
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology (2006) 1.18
2-acetylaminofluorene dose-dependent differentiation of rat oval cells into hepatocytes: confocal and electron microscopic studies. Hepatology (2004) 1.17
Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice. Gastroenterology (2011) 1.17
Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS One (2010) 1.17
The transcription factor GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One (2012) 1.17